Nitroglycerin vs Nitroprusside: Preload and Afterload
Nitroprusside’s cyanide and thiocyanate risks are distinct. Impaired hepatic function increases susceptibility to cyanide toxicity; impaired renal clearance particularly increases concern about thiocyanate accumulation.Source
How do nitroglycerin and nitroprusside differ?
Nitroglycerin and nitroprusside relax vascular smooth muscle through nitric-oxide signaling and increased cyclic GMP. Nitroglycerin’s venous effects predominate, reducing venous return and preload, although it also dilates arteries in a dose-related manner. Nitroprusside dilates arteries and veins more evenly, reducing afterload and preload. Their safety considerations also differ.
Key takeaways
- Nitroglycerin is relatively venoselective, rather than exclusively a venodilator.
- Nitroprusside rapidly lowers arterial resistance as well as venous return.
- PDE5 interactions and nitroprusside metabolites are different safety problems.
How does nitric-oxide signaling relax a vessel?
Nitric oxide activates soluble guanylate cyclase, which increases cyclic GMP inside vascular smooth muscle. This signaling changes contraction-related proteins and favors relaxation. The vessel’s response then changes its resistance or capacity.
Where the dominant effect occurs determines the hemodynamic result. Relaxing veins promotes peripheral pooling and reduces venous return. Relaxing arteries reduces the resistance against which the ventricle ejects blood.
Why do preload and afterload effects differ?
Nitroglycerin affects both vascular beds, with venous effects predominating. Lower venous return reduces ventricular filling pressure and wall stress. Its arterial effect becomes more evident as dose and exposure change.
Nitroprusside produces substantial arterial and venous dilation. It reduces the load opposing ejection as well as filling pressure. The comparison is a relative difference, so avoid describing either medication as acting on only one part of the circulation.
What safety distinction should you explain?
Both drugs cause hypotension. Nitroglycerin also has a dangerous interaction with phosphodiesterase 5 inhibitors, which reduce cyclic GMP breakdown and amplify the blood-pressure effect. Do not treat that interaction as a generic problem shared by every vasodilator.
Nitroprusside generates cyanide during metabolism, and much of that cyanide is converted into thiocyanate. Impaired hepatic function raises susceptibility to cyanide toxicity, while renal dysfunction increases concern about thiocyanate accumulation. Dose and exposure duration matter. Explain the vascular goal and these separate risks when comparing the drugs.
Reassess arterial pressure and perfusion after a change. A reduction in filling pressure is useful when it fits the patient’s hemodynamic problem, rather than as an isolated numerical goal.
